Radiopharm Theranostics Limited (AU:RAD) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Radiopharm Theranostics Limited has announced significant advancements in the development of its cancer-targeting radio-antibody BetaBart, including a successful pre-IND submission to the FDA and production of the first GMP batch. The collaboration with MD Anderson Cancer Center has yielded a promising molecule for a planned Phase I/II clinical trial aimed at multiple tumor types, leveraging the overexpression of B7-H3 in aggressive cancers. The company is on track for human trials by mid-2025, with secured supply chains for the necessary isotopes.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.